Drug-induced seizure liabilities produce significant compound attrition during drug discovery. Currently available in vitro cytotoxicity assays cannot predict all toxicity mechanisms due to the failure of these assays to predict sublethal targetspecific electrophysiological liabilities. Identification of seizurogenic and other electrophysiological effects at early stages of the drug development process is important to ensure that safe candidate compounds can be developed while chemical design is taking place, long before these liabilities are discovered in costly preclinical in vivo studies. The development of a high throughput and reliable in vitro assay to screen compounds for seizure liabilities would de-risk compounds significantly earlier in the drug discovery process and with greater dependability. Here we describe a method for screening compounds that utilizes rat cortical neurons plated onto multiwell microelectrode array plates to identify compounds that cause neurophysiological disruptions. Changes in 12 electrophysiological parameters (spike train descriptors) were measured after application of known seizurogenic compounds and the response pattern was mapped relative to negative controls, vehicle control and neurotoxic controls. Twenty chemicals with a variety of therapeutic indications and targets, including GABA A antagonists, glycine receptor antagonists, ion channel blockers, muscarinic agonist, d-opioid receptor agonist, dopaminergic D2/adrenergic receptor blocker and nonsteroidal anti-inflammatory drugs, were tested to assess this system. Sixteen of the seventeen seizurogenic/neurotoxic compounds tested positive for seizure liability or neurotoxicity, moreover, different endpoint response patterns for firing rate, burst characteristics and synchrony that distinguished the chemicals into groups relating to target and seizurogenic response emerged from the data. The negative and vehicle control compounds had no effect on neural activity. In conclusion, the multiwell microelectrode array platform using cryopreserved rat cortical neurons is a highly effective high throughput method for reliably screening seizure liabilities within an early de-risking drug development paradigm.
Seizures and neurotoxic responses pose a serious risk in the drug discovery and development process. These adverse central nervous system (CNS) effects are one of the most common reasons for the attrition of pharmaceutical drug discovery pipelines (Accardi et al., 2016) . Seizure liabilities are difficult to detect in early in vitro toxicology screening due to the inability of specific endpoint based assays to detect functional responses. Indeed, most toxicity assays report changes that occur in cell morphology or physiology based on biochemical pathways, receptor binding, ion channel function, or specific target-related alterations (McConnell et al., 2012) . Assessing changes in the normal function of a neural network can provide significant insights into the early effects of chemical or mechanical insults that are not detectable morphologically (Prado et al., 2005) or through typical toxicology-based endpoint assays . Thus far, robust and reliable high-throughput in vitro assays that detect neurophysiological disruptions have been lacking in the industry (Defranchi et al., 2011; Johnstone et al., 2010; McConnell et al., 2012) . The most commonly used method for in vitro assessment of neurotoxins and seizurogenic compounds is the hippocampal brain slice assay Easter et al., 2007; Wahab et al., 2010) . Although considered the gold standard for in vitro detection of seizurogenic potential, this technique lacks the throughput to screen large numbers of compounds and its success depends on a precise and successful tissue preparation along with, in some cases, complex electrophysiological recording equipment and significant available expertise.
Multiwell microelectrode arrays (MEAs), however, provide a moderately high-throughput method to evaluate electrophysiologically active tissues and cell types. This includes primary cardiac and neuronal cells as well as stem cell derived neuronal or cardiac cells (both induced pluripotent stem [iPS] cell and embryonic stem cell). MEA has the ability to record the electrical activity of excitable tissues without disrupting the integrity of the cells, thus providing a noninvasive platform for the evaluation of pharmaceutical and environmental chemical entities on CNS function (Johnstone et al., 2010) . Increased adoption of MEA as well as the development of higher throughput multiwell platforms have provided the industry with a robust, high-throughput approach to screening for neurological liabilities long before they are discovered in vivo or postapproval (Johnstone et al., 2010) .
The first successful recordings of neuronal action potentials by microelectrode arrays were conducted decades ago (Defranchi et al., 2011; Gramowski et al., 2004; Gross et al., 1977; Pine, 1980) . Consequently, MEAs have been used for studying responses to pharmacological agents, known toxins, mechanical and chemical challenges and to interrogate a variety of developmental neuronal processes (Defranchi et al., 2011; Gramowski et al., 2006; Robinette et al., 2011; Valdivia et al., 2014) . More recently, the low throughput weaknesses of early platforms has been improved with the evolution of MEAs (Johnstone et al., 2010; McConnell et al., 2012; Novellino et al., 2011; Valdivia et al., 2014) . This advancement facilitates the investigation of greater numbers of neural toxicants in concentration curves and enables high-throughput screening of potential new drug candidates for CNS effects.
The use of dissociated rat neuronal cultures is an accepted approach to studying electrophysiological, morphological and developmental neurobiology (Chiappalone et al., 2005; Otto et al., 2003; Quasthoff et al., 2015) . High throughput screening methods, such as neurite outgrowth using High-Content Imaging and automated patch clamp, are industry standards for in vitro assessment of potential neurotoxicity. When cultured on MEAs, rat neuronal cells exhibit normal functional electrophysiological characteristics such as spontaneous spike activity, selforganization, burst organization, synchronized network organization and responses to pharmacological and toxicological agents (Defranchi et al., 2011; Gramowski et al, 2000; Pasquale et al., 2008; Robinette et al., 2011) . Furthermore, cryopreserved rat cortical neurons introduce efficiencies in throughput, and when compared with freshly isolated neurons from embryonic rat cortex, have similar electrophysiological and immunocytochemical properties (Otto et al., 2003; Quasthoff et al., 2015) . When grown on MEAs for 3 weeks, no significant differences were reported between cryopreserved and freshly isolated rat cortical neurons on the formation and function of neural network bursting and synchrony (Quasthoff et al., 2015) . The use of cryopreserved neurons for in vitro assays also reduces the potential of variability associated with freshly isolated tissues, particularly if the same lot is validated and used for many experiments.
In our laboratory, cryopreserved primary rat cortical neurons plated on MEA plates elicit measurable spontaneous spike activity within 6-8 days after plating. By days 13-16, bursting and synchronized organization can be qualitatively observed and quantitatively measured. When plated with the same technique and conditions, rat cortical neurons from the same lot (lot to lot differences have been observed) will create a predictable and temporally consistent neural network amenable to screening new drug entities, agricultural chemicals and environmental toxins for their potential to cause neurotoxicity and alterations in neural network activity.
However, a high-throughput method also requires the establishment of clear criteria for classifying liabilities. We have developed a model based on changes in twelve electrophysiological parameters correlated with increased risk of seizure. This model was developed and tested using 15 known seizurogenic compounds and the response pattern was mapped relative to vehicle control, negative controls and neurotoxic controls. Response patterns of compounds with known targets were analyzed using MATLAB scripts customized for spike train analysis. The patterns of these changes produced phenotypic signatures of the known targets, while the negative and vehicle control compounds had no effect on neural activity. These results support the accuracy of this model as an in vitro screening tool for novel compounds to reliably predict seizurogenic liabilities.
MATERIALS AND METHODS

Chemicals.
A set of 15 proconvulsant compounds, 3 negative compounds and 2 neurotoxic compounds were chosen as a training set for the development of this model (Table 1 ). All chemicals were dissolved and serial diluted in 100% dimethyl sulfoxide (DMSO) at 500Â the treatment concentration. The known seizurogenic or neurotoxic compounds were treated at 4 or more different concentrations in triplicate per experiment. Negative compounds, acetaminophen and ibuprofen, were tested in triplicate at a single concentration, 50 mM, per experiment. The final assay concentration of DMSO was 0.2%, a concentration demonstrated to have no effect on the activity of the neurons (data not shown). DMSO 0.2% was included on all plates in triplicate as the vehicle control.
Cell culture. Axion BioSystems' 48-well MEA plates were used for all experiments. One day prior to plating neurons, MEA plates were precoated with 0.1% polyethyleneimine in a borate buffer solution for 1 h, rinsed with sterile laboratory grade water and allowed to dry overnight in a sterile hood. One hour before plating, a 15 ml laminin solution was dispensed directly over the electrode grid in each well and incubated at 37 C in a humidified environment . Commercially available cryopreserved primary rat cortical neurons (QBM Cell Sciences Ottawa, Ontario, Canada) prepared from dissociated brains of Sprague Dawley rats (E18-19) were used for all experiments. The neurons, which comprise a normal distribution of neurons and glia, were thawed and plated on precoated 48-well MEA plates by rapidly thawing and then slowly diluting them with neurobasal medium supplemented with 2% B27, 1% Penicillin-Streptomycin and 1% L-Glutamine (NB/B27 medium). To avoid osmotic shock, the dilution process was performed slowly in a drop-wise fashion until a 5-fold dilution was reached. After a centrifugation step, the cells were resuspended in NB/B27 medium and a 15 ml aliquot containing 75 000 cells was seeded in the center of the well directly over the electrode grid after removal of the laminin drop. The plates were placed in a humidified incubator at 37 C and 5% CO 2 for 2 h to allow sufficient attachment. At the end of Naturally produced by the seaweed Chondria armata and various diatoms of the genus Pseudonitzschia. Associated with outbreaks of gastrointestinal illnesses and neurotoxicity after the consumption of contaminated mussels and other filter feeding marine organisms Berman et al. (2002) , Lefebvre and Robertson (2010) the incubation period, 500 ml of NB/B27 medium was added to each well in a gentle 2-step process (250 ml for each step) to avoid detaching the neurons. The neurons were maintained in a humidified incubator at 37 C with 5% CO 2 for 13-16 days with 60% media changes 3 times a week before experimental procedures were performed.
Microelectrode array recordings. All recordings were acquired with Axion BioSystems' Maestro microelectrode array system (Axion Biosystems Atlanta, GA), a 768-channel high-throughput MEA platform, utilizing 48-well plates configured with 16 electrodes per well. Prior to compound addition, a baseline of spontaneous spike activity was recorded using the Maestro system controlled by Axion BioSystems' Integrated Studio (AxIS 2.3.3.5) software package. The assay was performed at 37 C with 5% CO 2 . The temperature was regulated by the Maestro while the premixed 5% CO 2 was delivered to the plate and maintained with the ECmini (Axion Biosystems Atlanta, GA). At 1-h postdose, an additional recording was obtained. Both of the raw data files (*.raw) were used to generate spike files (*.spk) using AxIS software's Spontaneous Neural Configuration which uses a Butterworth filter (high pass ¼ 200 Hz, low pass ¼ 3000 Hz) and spike detector setting consisting of an adaptive threshold crossing, with an adjusted 5.5 SD. The AxIS spike files were exported to MATLAB (Mathworks Natick, MA) for spike train analysis using customized scripts. Visualization tools (raster plots generated by Axion BioSystems' Neural Metric Tool and Nex Technologies, Herndon, VA' NeuroExplorer) were also employed to verify the quality and consistency of the activity in each well and to assist in the interpretation of the data. Prior to baseline recordings, an assessment of activity was performed for each well of the 48-well MEA with analysis of a 3-min recording. Wells with fewer than 8 active electrodes (minimum of 6.7 spikes/min) were eliminated from the experiment. Baseline recordings of approximately 15 min in length were obtained immediately before the addition of test compounds and controls. Following a 1-h incubation at 37 C with compounds, another 15-min recording was obtained. If a treated well fell below the activity threshold of 5 active electrodes due to compound effect, only spike count was determined and reported. No other parameters were calculated.
Compound preparation and treatment. Compounds were solubilized in 100% DMSO at 500Â the final concentration to be tested with a final DMSO concentration of 0.2%. All of the proconvulsant compounds (Table 1) were serially diluted in 100% DMSO for at least 4 concentrations and tested in triplicate per experiment. Positive controls, picrotoxin (GABA A antagonist) at a concentration of 10 mM and domoic acid (neurotoxin) at a concentration of 10 mM, and negative control DMSO 0.2% (vehicle) were included on all plates in triplicate. Each concentration for all compounds tested were in replicates of 3 per plate. The addition of all compounds and controls was performed by removing 250 ml of media from each well, diluting and mixing compound stock solutions into this conditioned media, and then returning the mixture to the appropriate wells. After the completion of compound addition, the cells were incubated for 1 h at 37 C with 5% CO 2 .
Spike train analysis. The disruption of networked spike trains by pharmacological intervention within microelectrode array wells results in observable qualitative changes in raster plot graphs of the spike trains, but in order to perform a quantitative statistical analysis of these changes, it is necessary to extract multivariate spike train descriptors from the raster data (Johnstone et al., 2010) . Numerous descriptors may be extracted from the data (Bologna et al., 2010; Johnstone et al., 2010; Keefer et al., 2001) , but conceptually, they fall into 3 categories: Activity measures (ie, firing rates), measures of spike train organization (ie, interspike interval [ISI] and burst statistics), and measures of crosschannel synchronization (ie, correlations between spike trains within wells). We have developed custom algorithms and MATLAB scripts to compute 39 different descriptors for quantifying changes in the spike train dynamics before and after compound treatments, and we have selected the most informative subset (described below) for compound screening. The spike train descriptors are computed for each of the 16 electrodes (or pairwise in the case of synchronization measures) per well, and are aggregated into descriptors for the entire well. In order to obtain a robust centroid estimate of each descriptor, it was required that each well have at least 5 active electrodes in order to have reliable data. Moreover, if 10 or more electrodes are active, only the 10 most active electrodes were used. An "active electrode" is defined by having at least 100 spike events in a 15-min interval. Once active electrodes are identified in each well, a median of each per channel descriptor is computed in order to obtain a robust centroid estimate of that descriptor per well. Synchronization descriptors are based on computing the median of all pairwise interactions between the active channels in a well.
Bursting patterns are thought to be integral to the transmission of information within in vivo systems, and therefore, burst analysis has received a great deal of interest in the literature. However, the lack of a well-defined definition of "burst" has resulted in the development of a vast variety of different algorithms (Gourevitch and Eggermont, 2007; Kapucu et al., 2012) , which produce results that are not necessarily satisfactory in all types of experiments. Therefore, burst detection methods are -generally chosen based on their ability to consistently reproduce results that an experimentalist would produce by manually parsing a spike train using a reasonable concept of a "burst". To date, the most widely used algorithm (Kapucu et al., 2012) is the Poisson-Surprise (PS) method (originally developed in Legendy and Salcman, 1985) . We developed our own variation of this method and verified its ability to parse spike trains into well-defined bursts for both control and baseline conditions as well as treatment group conditions that induce bursting. Specific implementation details include a PS threshold based on a p-value of .01, a condition that spikes separated by >0.5 s cannot reside in the same burst, a condition that bursts last <5 s, and a lower bound of 3 on the number of spikes in a burst. The algorithm is initiated by sweeping through the data to find 2 consecutive ISIs less than or equal to half of the mean ISI. If the PS is above the threshold, spikes are added to the candidate burst until the PS drops or the maximum ISI gap is reached. A moving window is then used to find the burst centroid and then expanded to either side to add spikes to maximize the PS. Spike train synchrony estimation is an important task in computational neuroscience due to the significance it has in neural communication. Therefore, synchronization-related descriptors may yield important information about undesirable drug effects. A frequently used method for assessing synchrony between channels (ie, spike trains) is the cross-correlogram, but it may present implementation difficulties due to the fact that it requires a carefully chosen discretization of time into bins. This problem has motivated a number of efforts to create continuous time spike train correlation methods (Park et al., 2008) , but these methods still contain parameters (eg, within kernel functions) that must be estimated for each pairwise spike train computation, and this issue presents challenges for an automated analysis of an entire multi-well plate with different treatment groups. We deduced that it would be ideal to utilize a parameter-free synchronization algorithm that could consistently produce reliable synchronization estimates for all wells regardless of large variability in activity between wells. We have verified that a novel method called the Inter-spike Interval Distance by Kreuz et al. (2007) for measuring spike train synchrony via an adaptive automatic time-binning procedure that requires no user specified free parameters yields excellent results with respect to detecting treatment-induced changes in synchronization that are clearly visible in raster plots of spike trains.
Spike train descriptors. The following subset of twelve endpoints generated from our custom MATLAB scripts were chosen to cover a range of changes elicited from different classes of compounds and pharmacological challenges as discovered during the development and validation of this assay (Table 2) .
RESULTS
This Assay Accurately Predicted the CNS Effects for 19 of the 20 Compounds Tested
We have developed an in vitro screening model for accurately predicting seizure liabilities using cryopreserved rat cortical neurons grown on multi-well microelectrode arrays. A training set of 20 compounds was used to determine their effects on spontaneous spike train activity. Custom MATLAB scripts were developed and used to quantify and report the data. When plated and maintained on MEAs, cryopreserved rat cortical neurons exhibit complex electrophysiological activity in the form of individual spikes, bursts and network synchrony. However, these characteristics are not well qualified or quantified by using only 1 or 2 salient endpoints (ie, spike rate, burst rate). Interestingly, when using firing rate alone, there is very little correlation with seizurogenic activity (Figure 1 ). In total 9 of the 14 compounds tested show little or no change in firing or a decrease in firing. Therefore, describing the complexities of a neural network may be more predictive and require endpoints that capture data points related to activity rates, burst characteristics and network characteristics. Furthermore, each of these categories may require multiple endpoints to ensure a complete analysis and understanding of the observed perturbations. Endpoints such as spike rate, burst rate, percent of spikes in bursts, burst duration, burst amplitude, burst area, ISI, ISI in burst, interburst interval, burst surprise, and synchronicity (Arnold et al., 2005; Gramowski et al., 2004 Gramowski et al., , 2006 Johnstone et al., 2010; Prado et al., 2005) have been used to describe spontaneous spike train activity. We generate 39 different descriptors for quantifying characteristics of the spike train dynamics using custom algorithms and MATLAB scripts. This comprehensive set of descriptors covers most aspects of spike and burst activity rates, burst characteristics and synchrony endpoints. Of these 39 endpoints, we selected a smaller informative set of 12 endpoints for reporting purposes. With this subset of endpoint descriptors, we are able to generate a robust and accurate quantitative assessment of spike activity and network Figure 2 illustrates the subset of descriptors used to quantify spontaneous spike train organization. This descriptor pattern enables a sensitive method of assessing changes in the neural activity elicited by the treatment of a chemical or drug entity. Based on the neuronal responses measured by the MEA and analyzed with these custom scripts, and with repeated testing, this model was determined to be both reliable and predictable for determining seizure potential of compounds. The chemical training set used was comprised of 15 proconvulsant compounds, 2 neurotoxic compounds, 2 compounds that have no effect on neural function and vehicle control. This assay accurately detected the proconvulsant activity for 14 of the 15 seizure causing compounds, with pilocarpine testing negative for seizure liability. Neurotoxins, domoic acid and tetrodotoxin, eliminated all spike activity at the concentrations tested. Negative controls, acetaminophen and ibuprofen, and vehicle control, DMSO 0.2%, did not alter spike activity in this assay. A majority of the compounds were tested over a range of concentrations with the minimal effective concentration (MEC) for causing a seizurogenic response in this model identified in Table 3 . For the 14 known seizurogenic compounds accurately identified, 2 very distinct and significant response patterns emerged. The concept of specific patterns of response, or "fingerprints" that emerge from spike train analyses of postdose MEA recordings has been described as a method for binning unknown neuroactive compounds into specific classes or targetrelated activity clusters (Gramowski et al., 2004 (Gramowski et al., , 2006 ) based on patterns. By looking at the response patterns that emerge from multiple endpoints describing activity rates, burst characteristics and synchrony, we have observed specific and unique patterns relating to neuroactive responses and seizurogenic potential. Here, we describe 2 distinct seizure prediction patterns (SPPs) that accurately predict the seizurogenic potential of different classes of chemicals. Although both patterns are unique and have distinct changes in endpoint directional values, they do have one common element; a change in the regularity of the spike trains after treatment with a seizurogenic compound. The first pattern, SPP1, increases the regularity of the burst characteristics and increases synchrony. The second pattern, SPP No. 2, increases the regularity of the spikes that occur outside of bursts and increases the regularity of the ISIs that occur with these spikes. Both patterns are recognizable through the qualitative inspection of the spike trains and quantifiable with analysis of the spike trains using our chosen descriptor set.
Seizure Prediction Pattern No. 1 Picrotoxin, gabazine, bicuculline, pentylenetetrazol, tutin, tranexamic acid, endosulfan, 4-aminopyridine. SPP1 is characterized by an overall increase in activity as observed by increases in firing and burst rates. More importantly, changes in burst organization and synchrony patterns elicited by compounds in this category have more significance that do the activity rates. The "burstiness" (Lei et al., 2011) of the spike trains increase as quantified with increases in the Number of Spikes in Bursts and consequent decreases in Percent Isolated Spikes. The ISI CV endpoint increases with the complete movement of spikes into bursts and the regularization of bursting, further signifying an increase in burstiness. The Normalized IQR Burst Duration decreases as burst duration becomes regularized. Burst Duration has a tendency to increase, particularly with the GABA A antagonists. Mean Interburst Intervals frequently decrease as the spike trains burst more regularly although this can be influenced by the baseline firing pattern. Also relevant in describing an increase in regularity is the decrease in Normalized mean absolute deviation (MAD) Burst Spike Number, an indicator of the statistical dispersion of the spikes in bursts. A decrease signifies regularity in the pattern of spikes within a burst as this is a calculation of the distance from each data value and the mean. Further indicators of a spike train that has progressed toward regularity are the Median/Mean ISI and the Median ISI. These endpoints will decrease as the spikes become more regular, consequently regulating the ISI as well. The synchrony endpoint, Mean of ISI Distance, will decrease as synchrony increases. This endpoint is very sensitive to any alterations in the synchrony of the electrodes within a well, and is therefore a very good indicator of synchronicity. Clearly, the compounds that fall into this pattern, most notably (but not exclusively) the GABA A antagonists, cause a substantial increase in synchrony and burst structure regularity, which is easily detected and reported in this assay. A dose response for picrotoxin, a GABA A antagonist, demonstrates the effect over multiple concentrations ( Figure 3A ) that give rise to this pattern of endpoint response. All of the concentrations would be considered positive for this response. When treated with picrotoxin at a concentration of 10 mM, the qualitative effect on spontaneous spike train activity shown in raster plots ( Figure 3B ) indicate a shift to a synchronous network bursting response when compared with the baseline activity. SPP1 can be observed for 6 additional GABA A antagonists in Figure 4A at concentrations that elicit a seizurogenic response in this model. Although 4-aminopyridine is a potassium channel blocker, its effect on spike train synchrony and burst characteristics ( Figure 4B ) is similar to the effects of the GABA A antagonists.
Seizure Prediction Pattern No. 2 NMDA, SNC80, linopirdine, strychnine, amoxapine, thioridazine. SPP2 is characterized by substantial decreases in firing and burst rates. Burst organization deteriorates and more spikes are detected outside of bursts, signified by a decrease in the Number of Spikes in Bursts and an increase in Percent Isolated Spikes. A further indicator of the collapse of organized bursting is evident with a decrease in ISI CV (decreased burstiness). For this pattern, Normalized IQR Burst Duration decreases due to the shortening of Burst Duration observed for most of the spike train. Mean interburst intervals tend to increase as bursting decreases and the mean of ISI Distance tends to be unaffected or slightly decreased. The Median/Mean ISI and Median ISI increase markedly as the spikes fall outside the confines of a burst. One of the most relevant endpoint changes observed with this pattern is the Normalized MAD Burst Spike Number endpoint. If this endpoint falls to zero after treatment, this is an indicator of a metered spike pattern/spike regularity, which is associated with this particular seizurogenic response. A dose response for strychnine demonstrates the effect over multiple concentrations ( Figure 5A ) that is indicative of the SPP2 pattern of response. When treated with strychnine at a concentration of 30 mM, the qualitative effect illustrated with the spontaneous raster plots ( Figure 5C ) indicate a breakdown in burst organization and synchrony with more spikes occurring independent of bursts in a metered pattern when compared with baseline activity. This is further demonstrated in the raster plots with NMDA at a concentration of 5 mM in Figure 5D . SPP2 can also be observed for SNC80, linopirdine, amoxapine, and thioridazine in Figure 5B at concentrations that elicit a seizurogenic response in this model. There is often a narrow concentration window where this pattern can be identified as the firing rate decreases substantially for many of these compounds which makes analysis difficult.
Pilocarpine did not consistently alter neural activity in this assay when treated up to 100 mM. Domoic acid at a concentration of 10 mM and tetrodotoxin at a concentration of 0.05 mM abolished all spike activity 1-h postdose. The negative controls, acetaminophen and ibuprofen, both at a concentration of 50 mM did not have an effect on neural activity in this assay. Vehicle control, 0.2% DMSO, did not have an effect on neural activity in this assay (Figure 6 ).
DISCUSSION
Adverse CNS effects are a significant reason for drug attrition in the pharmaceutical industry. Presently, a majority of nonclinical safety assessment techniques do not address these adversities with in vitro platforms . Addressing chemical or target-specific toxicity early in the discovery process can advantageously drive chemistry efforts away from toxic scaffolds or curtail huge investment in programs or targets plagued by toxicity (Roberts et al., 2014) . Undoubtedly, discovering toxic effects from a new chemical entity early in the process is the goal of most discovery units and is done with general cytotoxicity assays such as ion channel specific assays, receptor-binding assays and high-content screening assays. The industry, however, is lacking a robust, high throughput, in vitro assay that accurately predicts seizurogenic liabilities and electrophysiological neurotoxic effects. One in vitro assay currently used is the hippocampal brain slice assay, but this requires a significant amount of compound, expertise in the isolation and preparation of hippocampal slices and sophisticated instrumentation. Also noteworthy is a recent survey pertaining to CNS drug safety conducted by the Safety Pharmacology Society that concluded the hippocampal brain slice assay has been used by 30% of the scientists polled within the last 5 years . Moreover, the same survey showed that even <30% of CNS safety assessments use other in vitro techniques such as the use of neuronal cell lines, blood-brain barrier assays and stem cell derived neurons. Most CNS safety pharmacology studies are in vivo tests that are behavioral based studies, such as the Irwin assay and the functional observational battery test (Accardi et al., 2016) . These in vivo assessment assays are costly, require large quantities of chemical matter and are conducted later in the preclinical phase, usually after considerable investment has already occurred. MEA technology has provided the industry with a robust in vitro approach to identifying CNS liabilities long before in vivo testing ensues. Choice of a neuronal cell type is integral to the success of a seizure prediction model. Although other neuronal types such as hippocampal neurons have been implicated in epileptic phenotypes and have been used for seizure prediction, we found that rat cortical neurons gave the most robust response to the broadest range of chemical entities tested. Hippocampal cells synchronize rapidly during development in vitro, narrowing the temporal window needed for testing compounds that increase synchrony, such as GABA A antagonists. Although substantial changes can be observed in the spike trains of hippocampal cells after treatment with GABA A Figure 3 . Picrotoxin causes a seizurogenic response pattern when treated at multiple concentrations and measured 1-h postdose. A, Percent change from baseline and normalized to vehicle control wells, response of picrotoxin at 16.7, 5.6, 1.9, 0.6, and 0.2 lM. A consistent pattern of response is observed for all of the concentrations tested with a less robust response observed at the lowest concentrations tested. B, Raster plots of spontaneous spike activity from active electrodes in 1 well for baseline activity and 1-h postdose treatment with 10 lM picrotoxin. The data for the raster plot were generated on the Axion Maestro MEA and displays all 16 electrodes from 1 well of a 48-well plate. The raster plot was generated using Nex Technologies, Herndon, VA' NeuroExplorer analysis software.
antagonists, the minor changes in the synchrony endpoints limit the ability to classify seizure effects in this model. When grown on MEA plates, cryopreserved rat cortical neurons form neural networks with detectable spike activity within 6-8 days, and are amenable for testing pharmacological and chemical agents after 13 DIV. These cells mature more gradually toward a networked synchronized phenotype and have a more substantial increase in the synchrony endpoints upon treatment with GABA A antagonists. The MEA-based screening tool presented here was developed based on the sensitivity of responses in rat cortical neurons from 19 of 20 compounds tested, which correlated with expected clinical responses (Table 4) . Two distinct patterns of change were associated with proconvulsive compounds as described in the results section; SPP1 and SPP2. These patterns are illustrated in Table 5 with a heatmap of compound responses.
SPP1 is indicative, but not limited to, the response induced by GABA A antagonists. This phenotypic response is associated with increases in activity rates, increases in the regularity of burst structure and formation, and increases in synchrony across the neural network. Although an increase in spike rate is observed for most of the compounds that fall into this category, it is not necessarily imperative that this occur. Indeed, there are instances when an increase in spike rate is not observed. We rarely, however, observe decreases in firing or burst rates with this pattern, although as concentrations are increased, solubility or cytotoxicity may cause this to occur. It is the changes in patterns associated with burst structure and network synchrony that are most significant about this pattern. Compounds with this pattern are considered to have a seizurogenic profile.
The SPP2 phenotypic response is quite different in that it is associated with a reduction in spike and burst rates, a deconstruction in burst formation and it completely abolishes network synchrony. A regularity in the isolated spike activity is observed with a noticeable metered pattern of the spikes and ISIs. Compounds with this pattern are also considered to have a seizurogenic profile. Although the patterns associated with SPP1 and SPP2 are strikingly different, there is one key element each pattern possesses, and that is a change in regularity. For SPP1, the change in regularity is observed at the burst level with an increase in burst structure regularity and an increase in network burst regularity (synchrony) (Figs. 3 and 4) . For SPP2, the change in regularity is observed at the spike level with an increase in the regularity of ISIs and individual spike occurrences ( Figure 5 ). For this pattern, burst and network characteristics experience a breakdown in regularity.
Neurotoxins, domoic acid and tetrodotoxin, eliminated all spike activity at the concentrations tested. Interestingly, domoic acid does not affect viable cell count or neurite outgrowth up to the highest concentration tested in the MEA assay (10 mM) when cells were stained with b3 tubulin and Hoechst in a high-content imaging assay (data not shown). However, it is 100% effective in eliminating spike activity at 10 mM when tested on the MEA, demonstrating its neurotoxic but not cytotoxic effects. Additionally, cell viability can be determined postexperiment to determine whether the effects are electrophysiological or due to acute cytotoxicity. This can be achieved using an ATP assay or other possible colorimetric assays (Brown et al., 2017; Wallace et al., 2015) . The vehicle control, 0.2% DMSO, along with negative controls acetaminophen (50 mM) and ibuprofen (50 mM) did not have effects on neural activity. Pilocarpine, when tested up to 100 mM, had no significant effects on neural activity in this assay. Pilocarpine is used as a rat model for epilepsy. In this in vivo model, status epilepticus is induced by pilocarpine administration at a relatively high dose (380 mg/kg), and within 10-30 min, behavioral seizure activity ensues (Buckmaster, 2004) . After a prolonged duration of status epilepticus, brain injury and neuronal loss occur, producing an epileptic phenotype. It has been shown that the onset of seizures in this rat model of temporal lobe epilepsy begins primarily in the hippocampus region of the brain, similar to patients with temporal lobe epilepsy (Toyoda et al., 2013) . Variations on this in vivo model actually administer pilocarpine directly to the hippocampus (Buckmaster, 2004) . Given the fact that the hippocampus is the major region of the brain targeted by this model, perhaps the lack of effect we see in our model is attributed by the cell type we use, neurons from the rat cortex. Although rat cortical cells express varying muscarinic acetylcholine receptor subtypes at different periods of maturation, the hippocampus has been shown to express consistent muscarinic receptor subtypes throughout maturation (Tice, 1996) . This pattern of expression may be key to the lack of consistent response seen in cortical neurons. Further characterization at different timepoints and in different cell types would be required to definitively determine the reason, but we have observed significant pilocarpine induced effects with other cell types such as hiPS cell derived glutamatergic neurons (data not shown).
CONCLUSION
Until recently, the detection of neurotoxic and seizurogenic effects from chemical entities with a robust and high-throughput in vitro screening platform has been lacking. Most in vitro toxicity assays lack the ability to detect electrophysiological liabilities that effect neural network activity. However, the evolution of the multi-well microelectrode array has enabled the testing of networked, electrophysiologically active cell types, such as neurons, on a high-throughput platform. We have developed an MEA screening tool using cryopreserved rat cortical neurons and a novel computational model for spike train analysis, which provides a reliable approach for a high-throughput in vitro assessment of adverse CNS drug effects. In this study, we report a model that accurately predicted the seizurogenic potential of 14 out of 15 know proconvulsant compounds. Moreover, 2 clear and distinct patterns of seizurogenic responses emerged, emphasizing the sensitivity of the assay in identifying different types of effects from different classes of compounds. This ability to identify and characterize proconvulsant responses of compounds at relevant drug concentrations represents a significant advancement in the assessment of in vitro CNS safety and will allow for the progression of safer drugs moving forward. It will also result in a decrease in the need for animal testing for unexpected side effects such as seizures while also identifying liabilities much earlier in the drug discovery process. Additional compound classes including more positive seizurogenic compounds, negative control compounds, and a diverse set of neuroactive compounds are being screened to add to the scope of this work, as well as to further validate its utility for classifying and identifying compounds with seizurogenic potential. Further enhancements are also underway to expand this assay into human iPS cell-derived neurons to determine the ability to predict seizure liability in human cells.
ACKNOWLEDGMENTS
Jenifer A. Bradley and Christopher J. Strock acknowledge they are employed by Cyprotex US, An Evotec Company. Cyprotex US offers MEA contract screening for Neurotoxicity and 
